Mobivestin
Mobivestin Uses, Dosage, Side Effects, Food Interaction and all others data.
Mobivestin is a progestogen structurally related to norethisterone. It may be used alone or as the progestogenic component of some oral contraceptives.
| Trade Name | Mobivestin |
| Generic | Lynestrenol |
| Lynestrenol Other Names | Lynestrenol |
| Type | Tablet |
| Formula | C20H28O |
| Weight | Average: 284.443 Monoisotopic: 284.214015522 |
| Groups | Approved, Investigational |
| Therapeutic Class | Female Sex hormones, Oral Contraceptive preparations |
| Manufacturer | Macmillon Pharmaceuticals |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Mobivestin is used as a component of oral contraceptives in combination with an estrogen and is used in the treatment of gynecological disorders such as menstrual disorders
Mobivestin is also used to associated treatment for these conditions: Endometrial Carcinoma, Endometrial Hyperplasia, Endometriosis, Hypermenorrhea, Menstrual Distress (Dysmenorrhea), Menstruation, Metrorrhagia, Oligomenorrhoea, Polymenorrhoea, Primary Amenorrhoea, Secondary Amenorrhea, Oral Contraceptives
Dosage
Mobivestin dosage
Menstrual disorders: 5-10 mg daily as cyclic regimen.
Contraception: 0.5 mg daily when used alone or 0.75-2.5 mg daily when used in combination with an oestrogen.
Side Effects
GI disturbances, changes in appetite or weight, fluid retention, oedema, rashes, urticaria, mental depression, breast tenderness and pain, gynaecomastia, changes in libido, headache, migraine, altered menstrual cycle, irregular menstrual bleeding, changes in LFTs and serum lipid profile.
Precaution
CV or renal dysfunction, hypertension, epilepsy, migraine, asthma, DM, conditions which may be exacerbated by fluid retention, malabsorption syndrome, post ectopic pregnancy, functional ovarian cysts, thromboembolism. Lactation.
Interaction
Increased metabolism and subsequent reduction in efficacy with enzyme-inducing agents e.g. carbamazepine, griseofulvin, phenobarbital, phenytoin and rifampicin. Adjustment in antidiabetic dose may be required.
Pregnancy & Breastfeeding use
Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Contraindication
Undiagnosed vaginal bleeding, active venous thromboembolic disorders or severe arterial disease, hepatic impairment, progestogen-dependent tumours, porphyria. Pregnancy.
Innovators Monograph
You find simplified version here Mobivestin
